Exosomal microRNAs (miRNAs) have emerged as promising candidates for cancer biomarker discovery due to their unique properties as stable, non-invasive, and informative molecules in body fluids. These small, membrane-bound vesicles play critical roles in intercellular communication by transferring miRNAs, which regulate gene expression and influence various biological processes, including cancer progression, metastasis, and drug resistance. Recent advancements in exosome isolation and miRNA profiling technologies have unveiled their potential for early cancer detection, prognosis, and therapeutic monitoring. Exosomal miRNAs offer several advantages over traditional biomarkers, including ease of detection in liquid biopsies (e.g., blood, urine), the ability to reflect the molecular landscape of tumors, and their association with both primary and metastatic cancer sites. However, despite the growing body of evidence supporting their utility, challenges such as standardization of isolation methods, variability in miRNA expression across cancer types, and the need for large-scale clinical validation remain significant barriers to clinical translation. This review highlights the biological mechanisms by which exosomal miRNAs influence cancer biology, their clinical applications in cancer diagnosis and therapy, and the technological advancements driving their profiling. Additionally, we discuss the current challenges and future directions for harnessing exosomal miRNAs in precision oncology.
Cancer remains one of the foremost challenges in global health, distinguished by profound biological complexity, heterogeneity, and therapeutic resistance. Over recent decades, oncology has transitioned from broadly cytotoxic regimens toward molecularly targeted and immune-based therapies; nevertheless, substantial clinical gaps persist. The emergence of artificial intelligence (AI) represents a transformative advance in this continuum, offering unprecedented capacity to integrate and interpret multidimensional biomedical data. AI-driven methodologies now play pivotal roles in early cancer detection, histopathological and radiomic assessment, biomarker discovery, and the prediction of therapeutic response. Furthermore, AI is accelerating drug discovery and enabling adaptive, patient-specific treatment strategies that transcend conventional evidence-based paradigms. This review synthesizes recent progress at the interface of AI and oncology, highlighting how machine learning, deep learning, and computational modeling are reshaping diagnostic precision, therapeutic optimization, and clinical decision-making. We also examine persisting challenges, including data heterogeneity, algorithmic transparency, and ethical implementation in real-world settings. Integrating computational intelligence with precision medicine heralds a future of cancer care that is predictive, preventive, and personalized—where human expertise and AI converge to redefine the boundaries of cancer treatment.
Cancer remains one of the leading causes of death worldwide, demanding continuous innovation in therapeutic strategies. Traditional chemotherapeutic agents, though effective in certain contexts, are limited by systemic toxicity, drug resistance, and non-specific targeting. Over the past two decades, the landscape of anticancer drug discovery has undergone a paradigm shift with the emergence of molecularly targeted agents, immunotherapies, and rational drug design technologies. Advancements in genomics, proteomics, and structural biology have enabled the identification of novel cancer-specific targets, while computational and artificial intelligence (AI)-driven approaches are accelerating lead optimization and predictive modeling of drug efficacy and toxicity. The development of antibody–drug conjugates (ADCs), bispecific antibodies, and targeted protein degraders (PROTACs) represents a new generation of therapies capable of addressing previously “undruggable” targets. Meanwhile, patient-derived organoids, 3D co-culture systems, and high-content screening platforms are refining preclinical evaluation and improving translational success rates. This review summarizes the recent trends in anticancer drug discovery, highlights the integration of computational and experimental pipelines, and explores emerging modalities poised to redefine cancer treatment in the coming decade. The future of anticancer drug discovery lies in combining precision oncology, AI-based design, and systems-level modeling to deliver safer, more effective, and personalized therapies against cancer’s molecular complexity.
Cancer remains one of the leading causes of death worldwide, with traditional therapies like surgery, chemotherapy, and radiation being limited by toxicity and resistance. Recent breakthroughs in antibody-mediated therapies, precision medicine, and immunotherapies are reshaping the cancer treatment landscape. Monoclonal antibodies (mAbs), immune checkpoint inhibitors, and chimeric antigen receptor T-cell (CAR-T) therapies have proven to be highly effective, offering more targeted, less toxic alternatives to traditional treatments. Alongside these innovations, the integration of genomic profiling and next-generation sequencing (NGS) has paved the way for precision oncology, where therapies are tailored to the unique genetic makeup of a patient’s cancer. However, challenges such as tumor heterogeneity, therapy resistance, and immunotoxicity persist. This review discusses the mechanisms, clinical successes, and challenges associated with antibody-mediated therapies and precision medicine, as well as emerging treatment modalities. We also highlight the role of artificial intelligence (AI) in accelerating cancer research and improving therapeutic outcomes.
Cancer is a multifactorial disease influenced by genetic, epigenetic, and environmental determinants, including biological agents such as oncogenic viruses. Among these, hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) play pivotal roles in the pathogenesis of hepatocellular carcinoma (HCC)—the predominant form of primary liver cancer and a major contributor to global cancer mortality. Chronic infection with these hepatotropic viruses drives hepatocarcinogenesis through both direct mechanisms, including viral genome integration and oncoprotein expression, and indirect pathways involving persistent inflammation, immune evasion, and oxidative stress.Despite substantial advances in HBV vaccination programs and the development of curative therapies for HCV, the global burden of hepatitis-related liver cancer remains high, driven by underdiagnosis, limited access to care, and the absence of a functional cure for HBV.This review critically examines the molecular and pathogenic mechanisms by which HBV, HCV, and HDV contribute to cancer initiation and progression, and summarizes current therapeutic and preventive strategies. It further highlights emerging research directions and translational challenges that must be addressed to improve prevention, early detection, and treatment of virus-induced hepatocellular carcinoma.
Viruses contribute to a substantial fraction of human cancers globally, with an estimated 12–15% of all cancer cases being linked to viral infections. This review synthesizes the current understanding of oncogenic viruses, their mechanisms of viral carcinogenesis, and the types of cancers associated with different viral pathogens. We explore the evolving therapeutic landscape, including vaccines, immunotherapies, and oncolytic virotherapy, and discuss the latest advances in clinical trials. The review also examines the challenges of viral cancer treatment, such as immune evasion and resistance to therapies, and looks forward to promising future directions in personalised medicine, advanced viral therapies, and drug discovery. The intersection of virology and oncology offers new opportunities for cancer prevention and treatment that could transform patient outcomes globally.